Investor Relations :: Pieris Pharmaceuticals, Inc. (PIRS)

Latest News

Jan 10, 2023

Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346)

View Press Release

Nov 23, 2022

Pieris Pharmaceuticals To Present at Evercore ISI Healthconx Conference

Nov 9, 2022

Pieris Pharmaceuticals to Present at Jefferies London Healthcare Conference

View All News

Investor Presentation

View Presentation

Q3 2022

Quarter Ended Sep 30, 2022

Earnings Release

Earnings Webcast

10-Q

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Report

For Fiscal Year Ending Dec 31, 2021

Company Overview

Pieris is a clinical-stage biotechnology company that combines leading protein engineering capabilities and deep understanding into molecular drivers of disease to develop medicines that drive local biology to produce superior clinical outcomes for patients. Our pipeline includes inhalable Anticalin proteins to treat respiratory diseases and locally-activated bispecifics for immuno-oncology. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by respiratory and immuno-oncology focused partnerships with leading pharmaceutical companies.

View Management Team View Board of Directors

Investor Contact Information

Company

Pieris Pharmaceuticals, Inc.
225 Franklin St., Floor 26
Boston, MA 02110
USA
T: +1-857-246-8998
info@pieris.com

Investor Relations

T: +1-857-246-8998
investors@pieris.com

Transfer Agent

Computershare
P.O. Box 43006
Providence RI 02940-3078
T: 1-877-373-6374 (US, Canada, Puerto Rico) or 1-781-575-3100 (non-US)
web.queries@computershare.com
www.computershare.com/investor

Courier Delivery
150 Royall St.
Suite 101
Canton, MA 02021